Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer

Nature Genetics

Volumn 46, Issue 7, 2014, Pages 736-741

  Wang, Yufei ^a   McKay, James D ^b   Rafnar, Thorunn ^c   Wang, Zhaoming ^d   Timofeeva, Maria N ^b   Broderick, Peter ^a   Zong, Xuchen ^e   Laplana, Marina ^f   Wei, Yongyue ^g   Han, Younghun ^h   Lloyd, Amy ^a   Delahaye Sourdeix, Manon ^b   Chubb, Daniel ^a   Gaborieau, Valerie ^b   Wheeler, William ⁱ   Chatterjee, Nilanjan ^d   Thorleifsson, Gudmar ^c   Sulem, Patrick ^c   Liu, Geoffrey ^j   Kaaks, Rudolf ^f,k   Henrion, Marc ^a   Kinnersley, Ben ^a   Vallée, Maxime ^b   Lecalvez Kelm, Florence ^b   Stevens, Victoria L ^l   Gapstur, Susan M ^l   Chen, Wei V ^m   Zaridze, David ⁿ   Szeszenia Dabrowska, Neonilia ^o   Lissowska, Jolanta ^p   Rudnai, Peter ^q   Fabianova, Eleonora ^r   Mates, Dana ^s   Bencko, Vladimir ^t   Foretova, Lenka ^u   Janout, Vladimir ^v   Krokan, Hans E ^w   Gabrielsen, Maiken Elvestad ^w   Skorpen, Frank ^w   Vatten, Lars ^w   Njølstad, Inger ^x   Chen, Chu ^y   Goodman, Gary ^y   Benhamou, Simone ^z   Vooder, Tonu ^aa   Välk, Kristjan ^ab   Nelis, Mari ^ac,ad   Metspalu, Andres ^ac   Lener, Marcin ^ae   Lubiński, Jan ^ae   Johansson, Mattias ^b   Vineis, Paolo ^af,ag   Agudo, Antonio ^ah   Clavel Chapelon, Francoise ^z,ai,aj   Bueno De Mesquita, H Bas ^af,ak,al   Trichopoulos, Dimitrios ^g,am,an   Khaw, Kay Tee ^ao   Johansson, Mikael ^ap   Weiderpass, Elisabete ^x,aq,ar,as   Tjønneland, Anne ^at   Riboli, Elio ^af   Lathrop, Mark ^au   Scelo, Ghislaine ^b   Albanes, Demetrius ^d   Caporaso, Neil E ^d   Ye, Yuanqing ^av   Gu, Jian ^av   Wu, Xifeng ^av   Spitz, Margaret R ^aw   Dienemann, Hendrik ^k,ax   Rosenberger, Albert ^ay   Su, Li ^g   Matakidou, Athena ^az   Eisen, Timothy ^ba,bb   Stefansson, Kari ^c   Risch, Angela ^f,k   Chanock, Stephen J ^d   Christiani, David C ^g   Hung, Rayjean J ^e   Brennan, Paul ^b   Landi, Maria Teresa ^d   Houlston, Richard S ^a   Amos, Christopher I ^h   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c DECODE GENETICS   (Iceland)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h DARTMOUTH MEDICAL SCHOOL   (United States)

ⁱ INFORMATION MANAGEMENT SERVICES INC   (United States)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k German Center for Lung Research (DZL)   (Germany)

^l AMERICAN CANCER SOCIETY   (United States)

^m UNIVERSITY OF TEXAS   (United States)

ⁿ N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^o NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^p INSTITUTE OF ONCOLOGY   (Poland)

^q NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^r Regional Authority of Public Health   (Slovakia)

^s NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^t CHARLES UNIVERSITY   (Czech Republic)

^u MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^v PALACKÝ UNIVERSITY   (Czech Republic)

^w NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^x UNIVERSITY OF TROMSØ   (Norway)

^y Fred Hutchinson Cancer Research Center   (United States)

^z INSERM   (France)

^aa UNIVERSITY OF TARTU   (Estonia)

^ab UNIVERSITY OF BERGEN   (Norway)

^ac UNIVERSITY OF TARTU   (Estonia)

^ad UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^ae POMERANIAN MEDICAL UNIVERSITY   (Poland)

^af IMPERIAL COLLEGE LONDON   (United Kingdom)

^ag HuGeF Foundation   (Italy)

^ah CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^ai UNIVERSITÉ PARIS SACLAY   (France)

^aj INSTITUT GUSTAVE ROUSSY   (France)

^ak NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^al UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^am BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^an HELLENIC HEALTH FOUNDATION   (Greece)

^ao UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ap UMEÅ UNIVERSITY   (Sweden)

^aq CANCER REGISTRY OF NORWAY   (Norway)

^ar KAROLINSKA INSTITUTE   (Sweden)

^as FOLKHÄLSAN RESEARCH CENTER   (Finland)

^at DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^au FONDATION JEAN DAUSSET CEPH   (France)

^av UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^aw BAYLOR COLLEGE OF MEDICINE   (United States)

^ax UNIVERSITY OF HEIDELBERG   (Germany)

^ay UNIVERSITY OF GÖTTINGEN   (Germany)

^az CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^ba CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^bb ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CHECKPOINT KINASE 2;

ADULT; ARTICLE; CANCER RISK; CHROMOSOME 3Q; CONTROLLED STUDY; DNA DAMAGE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; BRCA2 PROTEIN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHECKPOINT KINASE 2; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 84903585835     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3002     Document Type: Article

References (68)

1. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Hung, R.J. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
3. Amos, C.I. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008).
4. Thorgeirsson, T.E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
5. McKay, J.D. et al. Lung cancer susceptibility locus at 5p15.33. Nat. Genet. 40, 1404-1406 (2008).
6. Wang, Y. et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 40, 1407-1409 (2008).
7. Hu, Z. et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat. Genet. 43, 792-796 (2011).
8. Miki, D. et al. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat. Genet. 42, 893-896 (2010).
9. Lan, Q. et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat. Genet. 44, 1330-1335 (2012).
10. Travis, W.D. et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc. Am. Thorac. Soc. 8, 381-385 (2011).
11. Broderick, P. et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 69, 6633-6641 (2009).
12. Landi, M.T. et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am. J. Hum. Genet. 85, 679-691 (2009).
13. Timofeeva, M.N. et al. Influence of common genetic variation on lung cancer risk: meta-analysis of 14,900 cases and 29,485 controls. Hum. Mol. Genet. 21, 4980-4995 (2012).
14. Shi, J. et al. Inherited variation at chromosome 12p13.33, including RAD52, influences the risk of squamous cell lung carcinoma. Cancer Discov. 2, 131-139 (2012).
15. Huang, Y.T. et al. Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer. Proc. Natl. Acad. Sci. USA 108, 16345-16350 (2011).
16. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227 (2009).
17. Mathieson, I. & McVean, G. Differential confounding of rare and common variants in spatially structured populations. Nat. Genet. 44, 243-246 (2012).
18. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
19. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
20. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353-361 (2013).
21. Akbari, M.R. et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 27, 1290-1296 (2008).
22. Martin, S.T. et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24, 3652-3656 (2005).
23. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310-1316 (1999).
24. van Asperen, C.J. et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42, 711-719 (2005).
25. McAllister, K.A. et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 62, 990-994 (2002).
26. Spain, B.H., Larson, C.J., Shihabuddin, L.S., Gage, F.H. & Verma, I.M. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc. Natl. Acad. Sci. USA 96, 13920-13925 (1999).
27. Yano, K. et al. Nuclear localization signals of the BRCA2 protein. Biochem. Biophys. Res. Commun. 270, 171-175 (2000).
28. Bahassi, E.M. et al. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27, 3977-3985 (2008).
29. Mazoyer, S. et al. A polymorphic stop codon in BRCA2. Nat. Genet. 14, 253-254 (1996).
30. Wu, K. et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 65, 417-426 (2005).
31. Brennan, P. et al. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum. Mol. Genet. 16, 1794-1801 (2007).
32. Cybulski, C. et al. Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 29, 762-765 (2008).
33. Han, F.F., Guo, C.L. & Liu, L.H. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol. 32, 329-335 (2013).
34. Flores, E.R. The roles of p63 in cancer. Cell Cycle 6, 300-304 (2007).
35. Katoh, I., Aisaki, K.I., Kurata, S.I., Ikawa, S. & Ikawa, Y. p51A (TAp63?), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 19, 3126-3130 (2000).
36. Petitjean, A. et al. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with ?Np73. Carcinogenesis 29, 273-281 (2008).
37. Hao, K. et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet. 8, e1003029 (2012).
38. Omenn, G.S. et al. The ?-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res. 54 (suppl. 7), 2038s-2043s (1994).
39. Scélo, G. et al. Occupational exposure to vinyl chloride, acrylonitrile and styrene and lung cancer risk (Europe). Cancer Causes Control 15, 445-452 (2004).
40. Feyler, A. et al. Point: myeloperoxidase ?463G?A polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 1550-1554 (2002).
41. Nelis, M. et al. Genetic structure of Europeans: a view from the North-East. PLoS ONE 4, e5472 (2009).
42. Välk, K. et al. Gene expression profiles of non-small cell lung cancer: survival prediction and new biomarkers. Oncology 79, 283-292 (2010).
43. Holmen, J. et al. The Nord-Trondelag Health Study 1995-97 (HUNT2): objectives, contents, methods and participation. Norsk Epidemiologi 13, 1932 (2003).
44. Landi, M.T. et al. Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer. BMC Public Health 8, 203 (2008).
45. ATBC Cancer Prevention Study Group. The ?-tocopherol, ?-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann. Epidemiol. 4, 1-10 (1994).
46. Hayes, R.B. et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat. Res. 592, 147-154 (2005).
47. Calle, E.E. et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94, 2490-2501 (2002).
48. Eisen, T., Matakidou, A. & Houlston, R. Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS). BMC Cancer 8, 244 (2008).
49. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
50. Su, L. et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis 27, 1024-1029 (2006).
51. Kong, A. et al. Parental origin of sequence variants associated with complex diseases. Nature 462, 868-874 (2009).
52. Styrkarsdottir, U. et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature 497, 517-520 (2013).
53. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
54. Boeing, H., Wahrendorf, J. & Becker, N. EPIC-Germany - a source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann. Nutr. Metab. 43, 195-204 (1999).
55. Dally, H. et al. The CYP3A41B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13, 607-618 (2003).
56. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97, 1305-1309 (2007).
57. Timofeeva, M.N. et al. Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol. Biomarkers Prev. 20, 2250-2261 (2011).
58. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 34, 816-834 (2010).
59. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat. Genet. 44, 955-959 (2012).
60. Zeggini, E. et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40, 638-645 (2008).
61. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. Nat. Rev. Genet. 11, 499-511 (2010).
62. Aulchenko, Y.S., Struchalin, M.V. & van Duijn, C.M. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11, 134 (2010).
63. Clayton, D.G. et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat. Genet. 37, 1243-1246 (2005).
64. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007).
65. Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. Measuring inconsistency in meta-analyses. Br. Med. J. 327, 557-560 (2003).
66. Johnson, A.D. et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938-2939 (2008).
67. Gabriel, S.B. et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
68. Thorgeirsson, T.E. et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 42, 448-453 (2010).